Communiqués MBX Biosciences, Inc.

Actions

MBX

US55287L1017

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
58,51 ^USD	+3,47%		+9,10%	+85,51%

16/09	Transcript : MBX Biosciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 08:30 AM
08/09	MBX Biosciences, Inc. annonce la nomination de Jeff Held au poste de Chief Legal Officer	CI

Communiqués

09/09	MBX Biosciences to Participate in Upcoming Investor Conferences	AQ
08/09	MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer	AQ
27/08	MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism	AQ
06/08	MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights	AQ
13/07	MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth	AQ
12/06	MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism	AQ
01/06	MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026	AQ
26/05	MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City	AQ
11/05	MBX Biosciences : May 2026 Obesity Day Presentation – Final	PU
11/05	MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing	AQ
07/05	MBX Biosciences : Company Overview - May 2026	PU
07/05	MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights	AQ
07/05	MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award	AQ
23/04	MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio	AQ
03/04	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
12/03	MBX Biosciences : Company Overview - March 2026	PU
12/03	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights	AQ
10/03	MBX Biosciences Appoints Karen Basbaum as Chief Business Officer	AQ
09/03	MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism	AQ
23/02	MBX Biosciences to Participate in Upcoming March Investor Conferences	AQ
11/02	MBX Biosciences to Participate in Upcoming Investor Conferences	AQ
22/01	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair	AQ
14/01	MBX Biosciences : Company Overview - January 2025	PU
11/01	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference	AQ
15/12	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13	AQ